Revolution Medicines (RVMD) Insider Lorence Kim Buys 3,127 Shares

Executive Insider Trades at Revolution Medicines

Recent regulatory filings detail insider transactions at Revolution Medicines, Inc. (NasdaqGS: RVMD), including an acquisition of 3,127 shares by Lorence Kim on June 18, 2026. This activity arrives alongside other executive trades during the same period. Chief Financial Officer Jack Anders executed multiple transactions in June, including a sale of 20,000 shares on June 24, 2026, at an average price of $168.33 under a planned trading program, alongside an acquisition of 20,000 shares on the same date. Additional June 18 transactions included 3,127 shares acquired by Sushil Patel and 1,191 shares picked up by Flavia Borellini.

Stock Price and Moving Averages

Shares of Revolution Medicines trade around $169.51, positioning the biotech firm between its 52-week low of $42.18 and its 52-week high of $224.31. The stock currently changes hands above its 200-day moving average of $140.41, though it sits below its shorter-term 50-day moving average of $199.22. With a market capitalization exceeding $41.3 billion, the company experiences regular volatility typical of clinical-stage oncology developers.

Recent Earnings and Financial Position

Revolution Medicines operates as a precision oncology company focused on therapies for RAS-addicted cancers. For the trailing period, the company reports an earnings per share of negative $8.87. Because the firm remains in its clinical development phase and is not yet profitable, it lacks a meaningful price-to-earnings ratio. Its forward P/E sits at negative 32.76. Investors look toward the company's next financial update scheduled for November 4, 2026.

Analysts Set New Price Targets

Wall Street firms maintain an active interest in the precision oncology developer, carrying a consensus rating of strong buy. On October 16, 2026, William Blair initiated coverage on the stock with an outperform rating. A day earlier on October 15, 2026, Needham reiterated its buy rating with a price target of $275.00. RBC Capital adjusted its target to $260.00 on October 14, 2026, following an earlier adjustment to $259.00 on October 8, 2026. Truist Securities maintained a buy rating on October 7, 2026, with a target of $240.00. Brookline Capital initiated coverage on September 28, 2026, with a buy rating and a $318.00 price target, while B of A Securities set a target of $265.00 on September 21, 2026, and Morgan Stanley initiated coverage with an overweight rating and a $255.00 target on September 10, 2026. These targets contribute to a consensus mean price target of $253.21 across 20 analyst opinions.

Company Background and Outlook

Headquartered in Redwood City, California, Revolution Medicines develops targeted therapies addressing RAS-addicted cancers through its pipeline of RAS(ON) inhibitors and companion inhibitors. Lead clinical candidates include daraxonrasib and elironrasib. As the company advances its mid- and late-stage clinical trials, market participants continue to monitor upcoming regulatory disclosures, executive transactions, and pipeline updates ahead of the late-year earnings report.